David Iben explained it best when he stated, “We don’t care about volatility as a risk.” Our main concern is preventing a permanent loss of capital. Given that debt is frequently implicated in business failures, it makes sense to take a close look at a company’s balance sheet when assessing its level of risk. It … Read more
Amdocs (NASDAQ:DOX) has had a steep decline in share price of 17% during the last three months. However, if you look closely, you could notice that given how markets typically reward companies with great financial health, its strong financials could suggest that the stock could potentially experience a gain in value over time. We made … Read more
This brings us to the topic of interest: ON Semiconductor Corporation (NASDAQ:ON). In recent months, there has been a notable fluctuation in the share price of the company on the NASDAQGS, with highs of US$108 and lows of US$88.17. Investors may have a better opportunity to enter the stock market and possibly purchase it at … Read more
With growing turbulence in the Middle East, Wall Street’s big 2023 argument about whether the US economy is destined for a recession is making a comeback. Business executives are preparing for a downturn due to elevated geopolitical risk, persistent inflationary pressures, rising bond yields, and the Federal Reserve’s “higher for longer” policy. Paul Knopp, the … Read more
This week, as major American corporations began their annual reporting season, executives spoke about the Israel-Hamas conflict and some of them started fundraising. “I just wanted to express how horrified the recent terrible attacks on Israel have made us all feel. Before discussing the earnings, Jamie Dimon, the CEO of JPMorgan Chase, stated during a … Read more
Issues are approaching the global economy in the form of battalions, not lone spies. They are pursuing this on several fronts in Europe, China, and the US. When combined with the resurgence of geopolitical tensions in the Middle East, those issues increase the likelihood that by mid-year there will be a global financial and economic … Read more
For the third time this year, Novo Nordisk increased its full-year revenue and operating profit forecast on Friday. This was due to the company’s strong sales of its diabetic treatment Ozempic and weight-loss drug Wegovy in the US. On the news, Novo’s stock surged almost 5% to a record high before caving in and closing … Read more
